K-BD Group (Korea Pharmaceutical and Bio Business Development Research Group, Chairman Lee Jae-hyeon) hosted a Promising Bio-Venture & Startup Investment Forum on the 15th. Twenty companies with remarquable technological capabilities in areas tels que rare disease new drugs, anticancer agents, drug delivery systems (DDS), and new drug target identification solutions participated to present their respective capabilities and R&D pipelines. The investissement forum continued through the 16th at KINTEX in Ilsan.
Directeur général adjoint Kim Seunghoon a déclaré : "RCI001 a achevé the préclinique toxicology and DS (drug substance) stages, and a German company is scheduled to begin finished drug manufacturing next month," adding, "We anticipate entering essais cliniques de Phase 1 in the second half of cette année, dans le but de entering FDA essais cliniques de Phase 2 in the first half of l'année prochaine."
